Lambro A. Johnson

Dr. Lambro A. Johnson

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
SWShun Jie Wun
Shun Jie Wun
LJLambro A. Johnson
Lambro A. Johnson
LYLv You
Lv You
RMRoss P McGeary
Ross P McGeary
TBThomas Brueck
Thomas Brueck
LGLuke W. Guddat
Luke W. Guddat

1 November 2020 in Analytical Biochemistry
Verified
Journal Article
Closed access
LJLambro A. Johnson
Lambro A. Johnson
JJJohn de Jersey
John de Jersey
PMPaul P. Masci
Paul P. Masci
KZKong-Nan Zhao
Kong-Nan Zhao
NBNigel C. Bennett
Nigel C. Bennett
MLMartin F. Lavin
Martin F. Lavin

30 May 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
KZKong-Nan Zhao
Kong-Nan Zhao
GDGoce Dimeski
Goce Dimeski
PMPaul Masci
Paul Masci
LJLambro A. Johnson
Lambro A. Johnson
JWJingjing Wang
Jingjing Wang
Martin LavinMartin Lavin
Martin Lavin
We recently reported the potential application of recombinant prothrombin activator ecarin (RAPClot™) in blood diagnostics. In a new study, we describe RAPClot™ as an additive to develop a novel blood collection prototype tube that produces the highest quality serum for accurate biochemical analyte determination. The drying process of the RAPClot™ tube generated minimal effect on the enzymatic activity of the prothrombin activator. According to the bioassays of thrombin activity and plasma clotting, γ-radiation (>25 kGy) resulted in a 30–40% loss of the enzymatic activity of the RAPClot™ tubes. However, a visual blood clotting assay revealed that the γ-radiation-sterilized RAPClot™ tubes showed a high capacity for clotting high-dose heparinized blood (8 U/mL) within 5 min. This was confirmed using Thrombelastography (TEG), indicating full clotting efficiency under anticoagulant conditions. The storage of the RAPClot™ tubes at room temperature (RT) for greater than 12 months resulted in the retention of efficient and effective clotting activity for heparinized blood in 342 s. Furthermore, the enzymatic activity of the RAPClot™ tubes sterilized with an electron-beam (EB) was significantly greater than that with γ-radiation. The EB-sterilized RAPClot™ tubes stored at RT for 251 days retained over 70% enzyme activity and clotted the heparinized blood in 340 s after 682 days. Preliminary clinical studies revealed in the two trials that 5 common analytes (K, Glu, lactate dehydrogenase (LD), Fe, and Phos) or 33 analytes determined in the second study in the γ-sterilized RAPClot™ tubes were similar to those in commercial tubes. In conclusion, the findings indicate that the novel RAPClot™ blood collection prototype tube has a significant advantage over current serum or lithium heparin plasma tubes for routine use in measuring biochemical analytes, confirming a promising application of RAPClot™ in clinical medicine.

17 November 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
KZKong-Nan Zhao
Kong-Nan Zhao
PMPaul Masci
Paul Masci
GDGoce Dimeski
Goce Dimeski
LJLambro A. Johnson
Lambro A. Johnson
MGMichael Grant
Michael Grant
Martin LavinMartin Lavin
Martin Lavin
We describe here the purification and cloning of a codon-optimized form of the snake prothrombin activator ecarin from the saw scaled viper (Echis carinatus) expressed in mammalian cells. Expression of recombinant ecarin (rEcarin) was carried out in human embryonic kidney cells (HEK) cells under conditions for the development and performance of a novel and scalable recombinant snake ecarin to industry standards. Clotting performance of the rEcarin was established in recalcified citrated whole blood, plasma, and fresh whole blood and found to be comparable to native ecarin (N-Ecarin). Furthermore, hemolysis was observed with N-Ecarin at relatively high doses in both recalcified citrated and fresh whole blood, while clotting was not observed with rEcarin, providing an important advantage for the recombinant form. In addition, rEcarin effectively clotted both recalcified citrated whole blood and fresh whole blood containing different anticoagulants including heparin, warfarin, dabigatran, Fondaparinux, rivaroxaban and apixaban, forming firm clots in the blood collection tubes. These results demonstrate that rEcarin efficiently clots normal blood as well as blood spiked with high concentrations of anticoagulants and has great potential as an additive to blood collection tubes to produce high quality serum for analyte analysis in diagnostic medicine.

30 November 2020 in Analytical Biochemistry
Verified
Journal Article
Closed access
THTyrone Humphries
Tyrone Humphries
LJLambro A. Johnson
Lambro A. Johnson
PMPaul P. Masci
Paul P. Masci
GGGlenda C. Gobe
Glenda C. Gobe
David VeseyDavid Vesey
David Vesey